Bridging Phase 2 and Phase 3 Pneumococcal Immunologic Data for Future Combination Vaccines
نویسندگان
چکیده
منابع مشابه
modeling loss data by phase-type distribution
بیمه گران همیشه بابت خسارات بیمه نامه های تحت پوشش خود نگران بوده و روش هایی را جستجو می کنند که بتوانند داده های خسارات گذشته را با هدف اتخاذ یک تصمیم بهینه مدل بندی نمایند. در این پژوهش توزیع های فیزتایپ در مدل بندی داده های خسارات معرفی شده که شامل استنباط آماری مربوطه و استفاده از الگوریتم em در برآورد پارامترهای توزیع است. در پایان امکان استفاده از این توزیع در مدل بندی داده های گروه بندی ...
A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
Despite the progress that has been made in other forms of cancer therapy, Provenge® (Sipuleucel-T) is the only FDA-approved vaccine for the treatment of cancer. To understand the current landscape of therapeutic oncology vaccines we performed a quantitative analysis of phase 2 and phase 3 therapeutic cancer vaccine trials. We highlight shifts in trends for the vaccine platforms examined, common...
متن کاملThe future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children.
Seven-valent pneumococcal conjugate vaccine (PCV7) was licensed in February 2000. In June 2000, the Advisory Committee on Immunization Practices and the American Academy of Pediatrics recommended the universal administration of pneumococcal conjugate vaccine for all children 23 months of age and younger and for children 24 to 59 months of age who are at high risk for serious pneumococcal diseas...
متن کاملA tale of 2 pneumococcal vaccines.
Pneumonia is the leading infectious cause of death in all age groups. After 4 decades with just a single bacterial vaccine to prevent the disease, we now have conjugate pneumococcal vaccines licensed across most age groups to complement the 23-valent pneumococcal polysaccharide vaccine (PPV23), which has been themainstay of efforts to protect persons aged >2 years from pneumococcal infections. ...
متن کاملDiscounting phase 2 results when planning phase 3 clinical trials.
Sample size planning is an important design consideration for a phase 3 trial. In this paper, we consider how to improve this planning when using data from phase 2 trials. We use an approach based on the concept of assurance. We consider adjusting phase 2 results because of two possible sources of bias. The first source arises from selecting compounds with pre-specified favourable phase 2 resul...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2001
ISSN: 1058-4838,1537-6591
DOI: 10.1086/322565